Skip to main content

Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy

Abstract

The aim of our current study was to demonstrate the efficacy and safety of vaporesection using a 120-W Tm:YAG laser (Revolix Duo) in patients with BPH receiving systemic anticoagulation or antiplatelet therapy. Between April 2010 and November 2011, a total of 76 patients using oral antiplatelet or anticoagulant (OA) agents affected by LUTS for BPH were underwent thulium vaporesection of the prostate (ThuVARP) using a 120-W 2-μm CW Tm:YAG laser and evaluated at 3- and 6-month follow-up. Of these, in 41 patients (group A) was performed vaporesection while receiving OA therapy. In 35 patients (group B), OA agents were discontinued 10 days before surgery. There were no significant differences in average vaporesection times, catheterization time, or hospital stay. There was no significant change in serum sodium level before and immediately after vaporesection in either group. Significant improvements compared to baseline were observed at each postoperative assessment in both groups for Qmax, PVR, IPSS, and QoL. More specifically, the IPSS score improved from 21.7 at baseline to 5.2 at 6 months in group A and from 20.7 to 4.5 in group B. At 6 months, Qmax increased 226 and 190 % for the 2 groups, respectively. The PVR decreased from 119 at baseline to 11 mL at 6 months in group A and from 125 to 11 mL in group B. ThuVARP is a safe and efficient procedure for patients with BPH, refractory to pharmacotherapy, who require active antiplatelet or anticoagulant therapy.

This is a preview of subscription content, access via your institution.

References

  1. Fitzpatrick JM (2006) The natural history of benign prostatic hyperplasia. BJU Int 97(Suppl 2):3–6; discussion 21-2

    Google Scholar 

  2. Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50:969–980

    PubMed  Article  Google Scholar 

  3. Rieken M, Ebinger Mundorff N, Bonkat G, Wyler S, Bachmann A (2010) Complications of laser prostatectomy: a review of recent data. World J Urol 28(1):53–62

    PubMed  Article  Google Scholar 

  4. Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, Gross AJ (2010) Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol 28(1):45–51

    PubMed  Article  Google Scholar 

  5. Szlauer R, Gotschl R, Razmaria A, Paras L, Schmeller NT (2009) Endoscopic vaporesection of the prostate using the continuous-wave 2-mm thulium laser: outcome and demonstration of the surgical technique. Eur Urol 55(2):368–375

    PubMed  Article  Google Scholar 

  6. Fu WJ, Zhang X, Yang Y, Hong BF, Gao JP, Cai W, Zhang P, Wang XX (2010) Comparison of 2-microm continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective nonrandomized trial with 1-year follow-up. Urology 75(1):194–199

    PubMed  Article  Google Scholar 

  7. Gupta N, Kumar R, Dogra PN, Seth A (2006) Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int 97(1):85–89

    PubMed  Article  Google Scholar 

  8. Fu WJ, Gao JP, Hong BF, Yang Y, Cai W, Zhang L (2008) Photoselective laser vaporization prostatectomy for acute urinary retention in China. J Endourol 22(3):539–543

    PubMed  Article  Google Scholar 

  9. Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ (2007) RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol 25(3):257–262

    PubMed  Article  Google Scholar 

  10. Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS, Häcker A (2008) Systematic evaluation of a recently introduced 2-micron continuous-wave thulium laser for vaporesection of the prostate. J Endourol 22(5):1041–1045

    PubMed  Article  Google Scholar 

  11. Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Yi-Nan Zhang YN (2008) Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol 53(2):382–389

    PubMed  Article  Google Scholar 

  12. Mattioli S, Muñoz R, Recasens R, Berbegal C, Cortada J, Urmeneta JM, Teichmann H (2008) Treatment of benign prostatic hyperplasia with the Revolix laser [Article in Spanish]. Arch Esp Urol 61(9):1037–1.043

    Google Scholar 

  13. Elzayat E, Habib E, Elhilali M (2006) Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 175(4):1428–1432

    PubMed  Article  CAS  Google Scholar 

  14. Parr NJ, Loh CS, Desmond AD (1989) Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br J Urol 64(6):623–625

    PubMed  Article  CAS  Google Scholar 

  15. Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A (2011) Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 29(2):211–216

    PubMed  Article  CAS  Google Scholar 

  16. Dotan ZA, Mor Y, Leibovitch I, Varon D, Golomb J, Duvdevani M, Ramon J (2002) The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 168(2):610–613

    PubMed  Article  CAS  Google Scholar 

  17. Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A (2011) Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 29(2):211–216

    PubMed  Article  CAS  Google Scholar 

  18. Taylor K, Filgate R, Guo DY, Macneil F (2011) A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int. 108(Suppl 2):45–50

    PubMed  Article  Google Scholar 

  19. Hoffman RM, MacDonald R, Wilt TJ (2004) Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev. (1):CD001987

  20. Larson TR (2002) Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy. Urology. 59:12–16

    PubMed  Article  Google Scholar 

  21. Chung DE, Wysock JS, Lee RK, Melamed SR, Kaplan SA, Te AE (2011) Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol 186(3):977–981

    PubMed  Article  Google Scholar 

  22. Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser TC, Sulser T, Bachmann A (2007) Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 51(4):1031–1041

    PubMed  Article  CAS  Google Scholar 

  23. Bach T, Huck N, Wezel F, Hacker A, Gross AJ, Michel MS (2010) 70 vs 120 W thulium:yttrium-aluminium-garnet 2 micron continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex vivo evaluation. BJU Int 106(3):368–372

    PubMed  Article  Google Scholar 

  24. Netsch C, Stoehrer M, Brüning M, Gabuev A, Bach T, Herrmann TR, Gross AJ (2013) Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. World J Urol. [Epub ahead of print]

  25. EAU Guidelines (2011) Laser-based treatments for bladder outlet obstruction (BOO) and benign prostatic enlargement (BPE). 29–34

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carlo Magno.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Macchione, L., Mucciardi, G., Gali’, A. et al. Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy. Int Urol Nephrol 45, 1545–1551 (2013). https://doi.org/10.1007/s11255-013-0487-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-013-0487-y

Keywords

  • Vaporesection
  • Prostatic hyperplasia
  • Tm:YAG laser
  • Lower urinary tract symptoms
  • Anticoagulant
  • Antiplatelet